¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 0Q&(j7`^@  
eN,9N]K  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© (vZ-0Ep}  
!Z:XSF[T  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© v f{{z%3T  
77O$^fG2  
1.Co-stimulators (or co-stimulating molecules) 7[;!enO  
b~,e(D9DG  
2.NK-kB <z,)4z++  
#\lvzMjCC  
3.Immunoglobulin superfamily z eT`kZ  
F&czD;F  
4.antigen-presenting cell (APC) p  lnH  
&/WM:]^?0)  
5.death domain -[-oz0`Sl{  
H u;"TG  
6.CCR and CXCR xjo`u:BH  
K/ On|C  
7.Lectin (or mitogen) )C8^'*!  
(46'#E z[F  
8.Clusters of differentiation, CD) ,]2?S5R  
?`U_|Yo  
9.B7 family 6AAvsu:  
3s!6rT_=)d  
10.Cytotoxic T lymphocyte, CTL) vzg^tJ  
|"SZpx  
11.IL-15 and IL-15 receptor (IL-15R) )sm 9%|.&  
NlEyT9  
12.MHC restriction AfTm#-R  
(WT\HR  
13.Affinity-chromatography m| ,Tk:xH  
3<r7"/5  
14.Cyctosprin A, CsA $k\bP9  
k2D*`\ D  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) uBbQJvL  
Z5q%L!4G  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© uQO5GDuK>  
r*`e%`HU  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 oWY3dc  
Qf=^C Q=lV  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ]20:8l'  
aH6j,R%  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ }h;Z_XF&  
?_gvI  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ,'(|,f42  
%0-oZL  
ÃâÒßѧרҵ£º u;t<rEC2  
lu{ *]!  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ QfEJU8/5d  
IE\RP!  
Ïû»¯ÄÚ¿Æ£º ^ ` yhN  
"Y+VNS  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ i 7]o[  
2@a'n@-  
ѪҺ²¡Ñ§×¨Òµ£º .vKgiIC:  
Vl1.]'p_  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛÌ³ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»